Kava hepatotoxicity: Comparative study of two structured quantitative methods for causality assessment

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 5, 2010, Pages 545-563

  Teschke, R ^a   Fuchs, J ^a   Bahre, R ^a   Genthner, A ^a   Wolff, A ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

causality assessment methods; herbal hepatotoxicity; kava; kava hepatotoxicity

Indexed keywords

KAVA EXTRACT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GERMANY; HUMAN; LIVER DISEASE; MALE; QUANTITATIVE ANALYSIS; SWITZERLAND;

ADULT; AGED; AGED, 80 AND OVER; BIOMETRY; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; KAVA; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; PHYTOTHERAPY; TIME FACTORS;

EID: 77956692082     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01131.x     Document Type: Article

References (35)

1. Chang CY, Schiano TD (2007) Review article: drug hepatotoxicity. Alimentary Pharmacology and Therapeutics, 25, 1135 1151.
2. Teschke R, Bahre R (2009) Severe hepatotoxicity by Indian Ayurvedic herbal products; a structured causality assessment. Annals of Hepatology, 8 in press).
3. Zimmerman HJ (1999) Hepatotoxicity.
4. Teschke R, Schwarzenboeck A, Hennermann KH (2008) Causality assessment in hepatotoxicity by drugs and dietary supplements. British Journal of Clinical Pharmacology, 66, 758 766.
5. Denham A, McIntyre M, Whitehouse J (2002) Kava-the unfolding story: report on a work-in-progress. Journal of Alternative Complementary Medicine, 8, 237 263.
6. Stevinson C, Huntley A, Ernst E (2002) A systematic review of the safety of kava extract in the treatment of anxiety. Drug Safety, 25, 251 261.
7. Teschke R, Gaus W, Loew D (2003) Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine, 10, 440 446.
8. Schulze J, Raasch W, Siegers CP (2003) Toxicity of kava pyrones, drug safety and precautions-a case study. Phytomedicine, 10 (Suppl. IV 68 73.
9. Loew D, Franz G (2003) Quality aspects of traditional and industrial kava-extracts. Phytomedicine, 10, 610 612.
10. Clouatre DL (2004) Kava kava: examining new reports of toxicity. Toxicology Letters, 150, 85 96.
11. Block KI, Gyllenhaal C, Mead MN (2004) Safety and efficacy of herbal sedatives in cancer care. Integrative Cancer Therapies, 3, 128 148.
12. Schmidt M, Morgan M, Bone K, McMillan J (2005) Kava: a risk-benefit assessment. In: Mills M, Bone K, eds. The essential guide to herbal safety.
13. Schmidt M. Is Kava Really Hepatotoxic? Available at: http://www.uni- muenster.de/imperia/md/content/pharmazeutische-biologie/-v/review.pdf. (last accessed September 21, 2009).
14. Teschke R, Schwarzenboeck A, Hennermann KH (2008) Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. European Journal of Gastroenterology and Hepatology, 20, 1182 1193.
15. Stickel F, Baumüller HM, Seitz K, Vasilakis D, Seitz G, Seitz HK, Schuppan D. (2003) Hepatitis induced by kava (piper methysticum rhizoma). Journal of Hepatology, 39, 62 67.
16. Rejection of drug risks, step II. As related to: Kava-Kava (Piper methysticum)-containing, and kavain-containing drugs, including homeopathic preparations with a final concentration up to, and including D4. Available at: http://www.bfarm.de/de-ver/arzneimittel/amrisiken/stufenplan/Besch-Kava-Final. pdf (last accessed September 21, 2009).
17. MCA (Medicines Control Agency) Line listing 14 February 2002.
18. EMEA (European Medicines Agency) Line listing 10 July 2002.
19. Maria VAJ, Victorino RMM (1997) Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology, 26, 664 669.
20. Danan G, Bénichou C (1993) Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. Journal of Clinical Epidemiology, 46, 1323 1330.
21. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanches de la Cuesta F (2001) Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology, 33, 123 130.
22. Kaplowitz N (2001) Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology, 33, 308 310.
23. Aithal GP, Rawlins MD, Day CP (2000) Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. Journal of Hepatology, 33, 949 952.
24. Lee WM (2000) Assessing causality in drug-induced liver injury. Journal of Hepatology, 33, 1003 1005.
25. Björnsson E, Olsson R (2006) Suspected drug-induced liver fatalities reported to the WHO database. Digestive and Liver Disease, 38, 33 38.
26. EMEA: Assessment of Case Reports Connected to Herbal Medicinal Products Containing Cimicifugae Racemosae Rhizoma (Black Cohosh, Root). Available at: http://www.emea.europa.eu/pdfs/human/hmpc/26925806en.pdf (accessed 18 July 2006).
27. Teschke R, Schwarzenboeck A (2009) Suspected hepatotoxicity by cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine, 16, 72 84.
28. Teschke R, Wolff A (2009) Kava hepatotoxicity: regulatory data selection and causality assessment. Digestive and Liver Disease, doi:.
29. Teschke R, Schwarzenboeck A, Akinci A (2008) Kava hepatotoxicity: a European view. The New Zealand Medical Journal, 121, 1283.
30. Teschke R, Genthner A, Wolff A (2009) Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. Journal of Ethnopharmacology, 123, 378 384.
31. Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. Annals of Hepatology in press).
32. Macedo AF, Marques FB, Ribeiro CF, Teixeira F (2003) Causality assessment of adverse, drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel, according to different levels of imputability. Journal of Clinical Pharmacy and Therapeutics, 28, 137 143.
33. Arimone Y, Miremont-Salamé G, Haramburu F, Molimard M, Moore N, Fourrier-Réglat A, Bégaud B (2007) Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. British Journal of Clinical Pharmacology, 64, 482 488.
34. Arimone Y, Bégaud B, Miremont-Salamé G, Fourrier-Réglat A, Moore N, Molimard M, Haramburu F (2005) Agreement of expert judgment in causality assessment of adverse drug reactions. European Journal of Clinical Pharmacology, 61, 169 173.
35. Macedo AF, Marques FB, Ribeiro CF (2006) Can decisional algorithms replace global introspection in the individual causality assessment of spontaneously reported ADRs? Drug Safety, 29, 697 702.